This article is more than 5 years old. Information may no longer be current.

VIDEO: Expert calls attention to barriers to PCSK9 inhibitor access

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SANTA ANA PUEBLO, N.M. — In this video, Seth J. Baum, MD, FASPC, discusses current challenges in access to PCSK9 inhibitors and how to surmount these barriers.

Barriers to PCSK9 inhibitor access are “extraordinarily problematic,” according to Baum, who is immediate past president of the American Society for Preventive Cardiology, chief medical officer of Excel Medical Clinical Trials and clinical affiliate professor of biomedical science at Florida Atlantic University in Boca Raton.

Baum highlights strategies to improve patient access to PCSK9 inhibitors, such as use of the ASPC app, which features a 10-step approach, single-page prior authorization and appeal letters, case studies, references to key papers, links to advocacy sites, information on specialty pharmacies and other resources.

Watch the video for more.